# Viking Therapeutics, Inc.: financial statements, quarterly

VKTX · Nasdaq · CIK 1607678 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vktx.md) · [Financials](/companies/vktx/financials.md) · [Filings](/companies/vktx/filings.md) · [Insiders](/companies/vktx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vktx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-116708.md) | [0.0 d](/filings/0001193125-26-046876.md) | [0.0](/filings/0000950170-25-058129.md) | [0.0](/filings/0000950170-25-097950.md) | [0.0](/filings/0001193125-25-247059.md) | [0.0 d](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-193315.md) | [0.0](/filings/0001193125-26-324219.md) | [0.0](/filings/0001193125-25-247059.md) | [0.0 d](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-193315.md) | [0.0](/filings/0001193125-26-324219.md) |
| Research and development | $m | [18.4](/filings/0000950170-24-116708.md) | [20.5 d](/filings/0001193125-26-046876.md) | [24.1](/filings/0000950170-25-058129.md) | [23.8](/filings/0000950170-25-097950.md) | [22.8](/filings/0001193125-25-247059.md) | [31.0 d](/filings/0001193125-26-046876.md) | [41.4](/filings/0001193125-26-193315.md) | [60.2](/filings/0001193125-26-324219.md) | [90.0](/filings/0001193125-25-247059.md) | [153 d](/filings/0001193125-26-046876.md) | [150](/filings/0001193125-26-193315.md) | [116](/filings/0001193125-26-324219.md) |
| Operating income | $m | [(27.3)](/filings/0000950170-24-116708.md) | [(29.3) d](/filings/0001193125-26-046876.md) | [(34.1)](/filings/0000950170-25-058129.md) | [(34.1)](/filings/0000950170-25-097950.md) | [(36.6)](/filings/0001193125-25-247059.md) | [(46.2) d](/filings/0001193125-26-046876.md) | [(55.5)](/filings/0001193125-26-193315.md) | [(74.6)](/filings/0001193125-26-324219.md) | [(98.6)](/filings/0001193125-25-247059.md) | [(165) d](/filings/0001193125-26-046876.md) | [(164)](/filings/0001193125-26-193315.md) | [(133)](/filings/0001193125-26-324219.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(22.5)](/filings/0000950170-24-116708.md) | [(24.6) d](/filings/0001193125-26-046876.md) | [(27.4)](/filings/0000950170-25-058129.md) | [(22.3)](/filings/0000950170-25-097950.md) | [(24.9)](/filings/0001193125-25-247059.md) | [(35.4) d](/filings/0001193125-26-046876.md) | [(45.6)](/filings/0001193125-26-193315.md) | [(65.6)](/filings/0001193125-26-324219.md) | [(90.8)](/filings/0001193125-25-247059.md) | [(158) d](/filings/0001193125-26-046876.md) | [(158)](/filings/0001193125-26-193315.md) | [(128)](/filings/0001193125-26-324219.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000950170-24-116708.md) | not reported | [(0.26)](/filings/0000950170-25-058129.md) | [(0.20)](/filings/0000950170-25-097950.md) | [(0.22)](/filings/0001193125-25-247059.md) | not reported | [(0.41)](/filings/0001193125-26-193315.md) | [(0.58)](/filings/0001193125-26-324219.md) | [(0.81)](/filings/0001193125-25-247059.md) | not reported | [(1.37)](/filings/0001193125-26-193315.md) | [(1.10)](/filings/0001193125-26-324219.md) |
| Basic EPS | $ per share | [(0.23)](/filings/0000950170-24-116708.md) | not reported | [(0.26)](/filings/0000950170-25-058129.md) | [(0.20)](/filings/0000950170-25-097950.md) | [(0.22)](/filings/0001193125-25-247059.md) | not reported | [(0.41)](/filings/0001193125-26-193315.md) | [(0.58)](/filings/0001193125-26-324219.md) | [(0.81)](/filings/0001193125-25-247059.md) | not reported | [(1.37)](/filings/0001193125-26-193315.md) | [(1.10)](/filings/0001193125-26-324219.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [37.2](/filings/0000950170-23-055259.md) | [55.5](/filings/0000950170-25-027824.md) | [196](/filings/0000950170-24-047833.md) | [43.9](/filings/0000950170-24-086111.md) | [50.3](/filings/0000950170-24-116708.md) | [26.7](/filings/0001193125-26-046876.md) | [37.9](/filings/0000950170-25-058129.md) | [33.9](/filings/0000950170-25-097950.md) | [100](/filings/0001193125-25-247059.md) | [166](/filings/0001193125-26-324219.md) | [118](/filings/0001193125-26-193315.md) | [126](/filings/0001193125-26-324219.md) |
| Current assets | $m | [381](/filings/0000950170-23-055259.md) | [367](/filings/0000950170-25-027824.md) | [966](/filings/0000950170-24-047833.md) | [946](/filings/0000950170-24-086111.md) | [937](/filings/0000950170-24-116708.md) | [907](/filings/0001193125-26-046876.md) | [866](/filings/0000950170-25-058129.md) | [827](/filings/0000950170-25-097950.md) | [739](/filings/0001193125-25-247059.md) | [716](/filings/0001193125-26-324219.md) | [608](/filings/0001193125-26-193315.md) | [518](/filings/0001193125-26-324219.md) |
| Total assets | $m | [383](/filings/0000950170-23-055259.md) | [368](/filings/0000950170-25-027824.md) | [968](/filings/0000950170-24-047833.md) | [947](/filings/0000950170-24-086111.md) | [938](/filings/0000950170-24-116708.md) | [908](/filings/0001193125-26-046876.md) | [867](/filings/0000950170-25-058129.md) | [828](/filings/0000950170-25-097950.md) | [739](/filings/0001193125-25-247059.md) | [716](/filings/0001193125-26-324219.md) | [608](/filings/0001193125-26-193315.md) | [522](/filings/0001193125-26-324219.md) |
| Current liabilities | $m | [13.4](/filings/0000950170-23-055259.md) | [19.1](/filings/0000950170-25-027824.md) | [32.8](/filings/0000950170-24-047833.md) | [25.1](/filings/0000950170-24-086111.md) | [25.7](/filings/0000950170-24-116708.md) | [27.4](/filings/0001193125-26-046876.md) | [19.6](/filings/0000950170-25-058129.md) | [32.0](/filings/0000950170-25-097950.md) | [26.1](/filings/0001193125-25-247059.md) | [76.7](/filings/0001193125-26-324219.md) | [106](/filings/0001193125-26-193315.md) | [110](/filings/0001193125-26-324219.md) |
| Total liabilities | $m | [14.4](/filings/0000950170-23-055259.md) | [20.1](/filings/0000950170-25-027824.md) | [33.6](/filings/0000950170-24-047833.md) | [25.9](/filings/0000950170-24-086111.md) | [26.4](/filings/0000950170-24-116708.md) | [28.0](/filings/0001193125-26-046876.md) | [20.1](/filings/0000950170-25-058129.md) | [32.4](/filings/0000950170-25-097950.md) | [26.4](/filings/0001193125-25-247059.md) | [76.7](/filings/0001193125-26-324219.md) | [106](/filings/0001193125-26-193315.md) | [114](/filings/0001193125-26-324219.md) |
| Shareholders' equity | $m | [368](/filings/0000950170-23-055259.md) | [348](/filings/0000950170-25-027824.md) | [934](/filings/0000950170-24-047833.md) | [921](/filings/0000950170-24-086111.md) | [911](/filings/0000950170-24-116708.md) | [880](/filings/0001193125-26-046876.md) | [847](/filings/0000950170-25-058129.md) | [795](/filings/0000950170-25-097950.md) | [713](/filings/0001193125-25-247059.md) | [639](/filings/0001193125-26-324219.md) | [502](/filings/0001193125-26-193315.md) | [408](/filings/0001193125-26-324219.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.7) d](/filings/0000950170-24-116708.md) | [(17.6) d](/filings/0001193125-26-046876.md) | [(6.1)](/filings/0000950170-25-058129.md) | [(28.5) d](/filings/0000950170-25-097950.md) | [(22.0) d](/filings/0001193125-25-247059.md) | [(31.2) d](/filings/0001193125-26-046876.md) | [(52.3)](/filings/0001193125-26-193315.md) | [(47.1) d](/filings/0001193125-26-324219.md) | [(94.0) d](/filings/0001193125-25-247059.md) | [(85.3) d](/filings/0001193125-26-046876.md) | [(114)](/filings/0001193125-26-193315.md) | [(125) d](/filings/0001193125-26-324219.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.5](/filings/0000950170-23-055259.md) | [78.4](/filings/0000950170-24-047833.md) | [99.0](/filings/0000950170-24-086111.md) | [99.8](/filings/0000950170-24-116708.md) | [103](/filings/0000950170-25-058129.md) | [110](/filings/0000950170-25-097950.md) | [111](/filings/0001193125-25-247059.md) | [112](/filings/0001193125-26-193315.md) | [112](/filings/0001193125-26-324219.md) | [112](/filings/0001193125-25-247059.md) | [116](/filings/0001193125-26-193315.md) | [116](/filings/0001193125-26-324219.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 116,652,937 at 2026-07-15, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-324219.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.